Erudio Healtherudio.com
Drug
Isatuximab trials: what clinicians said in public
No HCP commentary report on a trial studying isatuximab yet. Erudio has found public clinician commentary on 10 clinical trials studying isatuximab, including GMMG-HD7, ICARIA-MM, IKEMA and MIDAS. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| IKEMA NCT03275285 · Sanofi DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| MIDAS NCT04934475 · Intergroupe Francophone du Myelome DeepView → | newly diagnosed multiple myeloma eligible for autologous transplantation | Phase 3 | Deep | View | |||
| GMMG-HD7 NCT03617731 · University of Heidelberg Medical Center DeepView → | transplant-eligible newly diagnosed multiple myeloma | Phase 3 | Deep | View | |||
| ICARIA-MM NCT02990338 · Sanofi DeepView → | relapsed and refractory multiple myeloma | Phase 3 | Deep | View | |||
| IZALCO NCT05704049 · Sanofi StandardView → | relapsed/refractory multiple myeloma | Phase 2 | Standard | View | |||
| NCT02513186 NCT02513186 · Sanofi FocusedView → | newly diagnosed multiple myeloma without immediate transplantation | Phase 1 | Focused | View | |||
| SWOG S1702 NCT03499808 · SWOG Cancer Research Network FocusedView → | relapsed and/or refractory AL amyloidosis | Phase 2 | Focused | View | |||
| IMROZ NCT03319667 · Sanofi FocusedView → | transplant-ineligible newly diagnosed multiple myeloma | Phase 3 | Focused | View | |||
| CC-92480-MM-002 NCT03989414 · Celgene FocusedView → | relapsed, refractory or newly diagnosed multiple myeloma | Phase 1/Phase 2 | Focused | View | |||
| NCT03530683 NCT03530683 · Pfizer FocusedView → | advanced hematologic malignancies | Phase 1 | Focused | View | |||